BUCK INSTITUTE FOR AGE RESEARCH
Grant: $438,300 - National Institutes of Health - Sep. 29, 2009
No votes have been cast for this award yet
Join the conversation: Post a comment about this award
Award Description: Aging is the single largest risk factor for disease in developed countries. The ongoing demographic change in the American population is greatly increasing the proportion of the population at risk for socially and economically important age-related diseases including Parkinson’s disease (PD), Alzheimer’s Disease and cancer. Age-related disease is arguably the single greatest challenge for biomedicine in the 21st Century. Age-related diseases increasingly represent a national emergency; one that may undermine the mid-term benefits of the American Recovery and Reinvestment Act (ARRA). Prompted by our prior discovery of compounds which extend lifespan and protect against stress we proposed in the parent grant to find new compounds that slow aging rates of the nematode C. elegans and determine the mechanisms at play. We expected such work to open new avenues for development of therapeutics for age-related diseases. We have made the striking discovery that a group of compounds commonly used to stain aggregating proteins in neurological disease increase the normal lifespan of C. elegans. Moreover, we find evidence that the compounds, especially thioflavin T (ThT) are slowing in vivo protein aggregate formation. The compounds have been previously used in human clinical studies. We previously discovered that Lithium, commonly used as a drug for the treatment of biopolar disorder, extends C. elegans lifespan. We believe Lithium acts via a distinct mechanism involving epigenetic modifications. We now propose to extend the scope of the grant to investigate the mechanisms at play for both these interesting interventions. It is important to follow BOTH leads at this time because it appears they act by different mechanisms. By pursuing two potential mechanisms to slow aging, we are more likely to find an intervention with significance to human aging and age-related disease. Since Lithium is already a drug in widespread use and ThT has been used in clinical research the likelihood that this proposal will lead to translational research in aging appears high.
Project Description: As defined in the award description field.
Jobs Summary: N/A (Total jobs reported: 0)
Project Status: Not Started
This award's data was last updated on Sep. 29, 2009. Help expand these official descriptions using the wiki below.
No comments have been added for this project.